Stockwatch

Advanced Proteome Therapeutics Corp
Symbol	APC
Shares Issued	104,990,903
Close 2014-07-23	C$ 0.24
Market Cap	C$ 25,197,817
Recent Sedar Documents

Advanced Proteome holders elect three directors at AGM

2014-07-24 10:48 ET - News Release

Shewchuk Subject: Advanced Proteome Therapeutics Corporation - Press Release Please disseminate the enclosed press release. Linda Shewchuk Securities Paralegal Corporate Office - Canada Advanced Proteome Therapeutics Corporation 401 - 1231 Barclay Street Vancouver, BC V6E 1H5 Tel: (604) 200-7855 Toll Free: (888) 909-4767 Cell: (604) 306-8854 Fax: (604) 259-0339 Email: missy222@telus.net File: 2014-07-24 Press Release.docx ADVANCED PROTEOME ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING, ENTERS INTO INVESTOR RELATIONS AGREEMENT July 24, 2014 Trading Symbol: TSX-V: APC VANCOUVER, BRITISH COLUMBIA - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) announces that the 2014 Annual General Meeting of Shareholders (the "Meeting") was held on Tuesday, July 22, 2014, at which Meeting all resolutions were approved. The resolutions passed at the Meeting include the following: 1. The number of directors for the ensuing year was set at three (3). 2. The following individuals were re-elected directors of the Company: Alexander (Allen) Krantz, Jean M. Bellin and Gary W. Hayes. 3. Dale Matheson Carr-Hilton LaBonte LLP, Chartered Accountants, was re-appointed as auditor of the Company. 4. Adoption of the Company's 10% rolling share option plan was ratified and approved. 5. Adoption of the Company's Advance Notice Policy was ratified and approved. The Board of Directors appointed Alexander (Allen) Krantz as President, Chief Executive Officer and Secretary, and Kenneth C. Phillippe as Chief Financial Officer for the ensuing year. Alexander (Allen) Krantz, Jean Bellin and Gary W. Hayes were appointed members of the Audit Committee, of which Jean Bellin is the Chair. The Company also announces that it has retained Mr. Scott Young to provide investor relations services and assist the Company in fostering productive, continuing dialogues with analysts, brokers, investors or other financial professionals. Mr. Young, who is based in Ontario, has spent the past 12 years working in the capital markets sector, inclusive of 10 years as VP of Business Development, Corporate Development and Investor Relations for biotechnology, technology and mining companies. He specializes in biotechnology and technology companies, assisting clients to communicate effectively to build an avid audience and develop strong relationships with potential investors. Besides his activities throughout Canada, Scott has extensive contacts in Asia, Africa, Europe, North and South America. The investor relations agreement is for an initial period of twelve months, with an option to renew for a further term at the mutual agreement of both parties. In compensation, the Company has granted Mr. Young an option to purchase 200,000 common shares, exercisable for a period of one year at an exercise price of $0.25 per share. The options are granted pursuant to the Company's Stock Option Plan and will vest in accordance with the provisions therein and the policies of the TSX Venture Exchange, which require that options granted to a consultant providing investor relations services must vest in stages over 12 months with no more than one-quarter of the options vesting in any three month period. This will bring the total number of options outstanding under the Stock Option Plan to 6,440,000 with 4,064,590 remaining available for grant. The investor relations agreement is subject to approval by the TSX Venture Exchange About APC APC has been applying its Foundation TrinityTM Technology to proteins targeted for the treatment of cancers. Advanced targeted therapies are designed to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics' market in the near future. The Company's goals are not only to employ therapy targeted for tumor cells, but also to deliver combination therapy in a single, pure therapeutic agent. To achieve this end, it has been the Company's intention to utilize a unique protein (and related systems), not only as a delivery vehicle to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface - both key to efficient manufacturing and product development. The protein vehicle has emerged as a potential immunotherapeutic as it is implicated in activating the immune system to attack and help clear tumor cells. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry. ON BEHALF OF THE BOARD Alexander (Allen) Krantz President and Chief Executive Officer FOR FURTHER INFORMATION PLEASE CONTACT: Advanced Proteome Therapeutics Corporation Tel: (617) 638-0340 http://www.advancedproteome.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.